SG&A Efficiency Analysis: Comparing Vertex Pharmaceuticals Incorporated and Geron Corporation

Biotech Giants' SG&A Strategies: Vertex vs. Geron

__timestampGeron CorporationVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201416758000305409000
Thursday, January 1, 201517793000377080000
Friday, January 1, 201618761000432829000
Sunday, January 1, 201719287000496079000
Monday, January 1, 201818707000557616000
Tuesday, January 1, 201920893000658498000
Wednesday, January 1, 202025678000770456000
Friday, January 1, 202129665000840100000
Saturday, January 1, 202243628000944700000
Sunday, January 1, 2023691350001136600000
Loading chart...

Unveiling the hidden dimensions of data

SG&A Efficiency: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing operational costs is crucial for success. Over the past decade, Vertex Pharmaceuticals Incorporated and Geron Corporation have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Vertex's SG&A expenses surged by approximately 272%, reflecting its aggressive expansion and investment in innovation. In contrast, Geron Corporation's expenses grew by about 312%, indicating a more conservative yet steady approach.

Key Insights

  • Vertex Pharmaceuticals: By 2023, Vertex's SG&A expenses reached over $1.1 billion, showcasing its commitment to maintaining a robust market presence.
  • Geron Corporation: Despite a smaller scale, Geron's expenses rose to nearly $69 million, highlighting its strategic focus on sustainable growth.

This analysis underscores the diverse strategies employed by biotech firms in navigating the complexities of the industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025